» Articles » PMID: 12209623

Virus Clearance and Immunopathology by CD8(+) T Cells During Infection with Respiratory Syncytial Virus Are Mediated by IFN-gamma

Overview
Journal Eur J Immunol
Date 2002 Sep 5
PMID 12209623
Citations 71
Authors
Affiliations
Soon will be listed here.
Abstract

CD8(+) T cells (CTL) are important effector cells for virus control and immunopathology after primary infection with respiratory syncytial virus (RSV). To investigate the effector mechanisms involved, we set up an adoptive transfer model, in which effector CTL specific for p82-90 of RSV M2 were generated in vivo, followed by short-term restimulation in vitro and transfusion into infected recipients. A total of 4 x 10(4) donor-derived p82-specific CTL homing to the lung within 4 days after transfusion were sufficient to completely eliminate a virusinoculum of 1.5 x 10(6) pfu. This was accompanied by significant lung pathology. Surprisingly, virus control and immunopathology proceeded unimpaired when donor cells lacking perforin, CD95 ligand or TNF were transfused. By contrast, treatment of recipient mice with a neutralizing antibody against IFN-gamma or transfusion of IFN-gamma-deficient effector CTL largely abolished virus control and significantly reduced CD8(+) T cell-mediated pathology. In IFN-gamma-deficient mice, high-dose primary infection experiments revealed attenuated immunopathology, but only slightly delayedvirus clearance, suggesting that other cells and molecules can partly substitute for the effects of CTL-derived IFN-gamma on virus clearance. These experiments identify IFN-gamma as a key molecule in RSV-induced immunopathology and in CD8(+) T cell-mediated control of RSV infection.

Citing Articles

Early Activation of Lung CD8 T Cells After Immunization with Live Malaria Sporozoites.

van Schuijlenburg R, Naar C, van der Wees S, Chevalley-Maurel S, Duszenko N, de Bes-Roeleveld H Pathog Immun. 2025; 10(2):46-68.

PMID: 40062354 PMC: 11888604. DOI: 10.20411/pai.v10i2.794.


Robust and Long-Lasting Immunity and Protection in Mice Induced by Lipopolyplex-Delivered mRNA Vaccines Expressing the Prefusion Protein of Respiratory Syncytial Virus.

Shan X, Han R, Cheng X, Bing J, Qi Z, Sun S Vaccines (Basel). 2025; 13(1).

PMID: 39852872 PMC: 11769257. DOI: 10.3390/vaccines13010093.


Host Responses to Respiratory Syncytial Virus Infection.

Agac A, Kolbe S, Ludlow M, Osterhaus A, Meineke R, Rimmelzwaan G Viruses. 2023; 15(10).

PMID: 37896776 PMC: 10611157. DOI: 10.3390/v15101999.


Virus-Like Particles Assembled Using Respiratory Syncytial Virus Matrix Protein Elicit Protective Immunity in Mice.

Lee S, Chu K, Kim M, Quan F Infect Drug Resist. 2023; 16:6099-6110.

PMID: 37719656 PMC: 10503551. DOI: 10.2147/IDR.S426039.


IgGκ Signal Peptide Enhances the Efficacy of an Influenza Vector Vaccine against Respiratory Syncytial Virus Infection in Mice.

Pulkina A, Vasilyev K, Muzhikyan A, Sergeeva M, Romanovskaya-Romanko E, Shurygina A Int J Mol Sci. 2023; 24(14).

PMID: 37511205 PMC: 10380829. DOI: 10.3390/ijms241411445.